All In Biotech

Drug Trial Radar · NCT02004691

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Dec 18, 2015

Primary completion

Mar 15, 2021

Study completion Oct 19, 2023

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: The primary objective of this phase 2/3 study was to evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once every 2 weeks for 52 weeks in adult participants with acid sphingomyelinase deficiency (ASMD) by assessing changes in: 1) spleen volume as measured by abdominal magnetic resonance imaging (MRI) (and, for the United States \[US\] only, in association with participant perception related to spleen volume as measured by splenomegaly-related score \[SRS\]); and 2) infiltrative lung disease as measured by the pulmonary function test, diffusing capacity of the lung for carbon monoxide (DLCO). Secondary Objectives: * To confirm the safety of olipudase alfa administered intravenously once every 2 weeks for 52 weeks. * To characterize the effect of olipudase alfa on the participant perception related to spleen volume as measured by the SRS after 52 weeks of study drug administration. (For the US, the effect of olipudase alfa on the SRS is part of the primary objective). * To characterize the effect of olipudase alfa after 52 weeks of study drug administration on the following outcome measures assessed sequentially: * The effect of olipudase alfa on liver volume; * The effect of olipudase alfa on platelet count; * The effect of olipudase alfa on fatigue; * The effect of olipudase alfa on pain; * The effect of olipudase alfa on dyspnea.

Conditions

  • Sphingomyelin Lipidosis

Interventions

  • placebo (saline)Drug

    Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo. Route of administration: intravenous infusion

  • Olipudase alfaDrug

    Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants. Route of administration: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at BaselineTime frame: Baseline (Day 1)
  2. Percent Change From Baseline in Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Week 52Time frame: Baseline, Week 52
  3. Combination Spleen Endpoint: Component 1: Spleen Volume (in MN) at BaselineTime frame: Baseline (Day 1)
  4. Combination Spleen Endpoint: Component 1: Percent Change From Baseline in Spleen Volume (in MN) at Week 52Time frame: Baseline, Week 52
  5. Combination Spleen Endpoint (Primary for US Only): Component 2: Splenomegaly-Related Score (SRS) at BaselineTime frame: Baseline (Day 1)
  6. Combination Spleen Endpoint (Primary for US Only): Component 2: Change From Baseline in Splenomegaly-Related Score (SRS) at Week 52Time frame: Baseline, Week 52

Locations

24 sites in 17 countries. Site status is shown where the registry gives one.

  • UCSF Medical Center Site Number : 840005

    San Francisco, California

  • Emory University Site Number : 840003

    Decatur, Georgia

  • Montefiore Medical Center Site Number : 840006

    The Bronx, New York

  • Investigational Site Number : 032001

    Córdoba, Argentina

  • Investigational Site Number : 036001

    Westmead, New South Wales, Australia

  • Investigational Site Number : 056001

    Leuven, Belgium

  • Hospital De Clinicas De Porto Alegre Site Number : 076001

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site Number : 100001

    Sofia, Bulgaria

  • Investigational Site Number : 152001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 250001

    Paris, France

  • Investigational Site Number : 276001

    Mainz, Germany

  • Investigational Site Number : 380002

    Naples, Italy

  • Investigational Site Number : 380001

    Udine, Italy

  • Investigational Site Number : 392001

    Fukushima, Fukushima, Japan

  • Investigational Site Number : 528001

    Amsterdam, Netherlands

  • Investigational Site Number : 620002

    Porto, Portugal

  • Investigational Site Number : 724001

    Madrid, Spain

  • Investigational Site Number : 788001

    Tunis, Tunisia

  • Investigational Site Number : 792002

    Ankara, Turkey (Türkiye)

  • Investigational Site Number : 792004

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number : 792003

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number : 792001

    Izmir, Turkey (Türkiye)

  • Investigational Site Number : 826002

    Birmingham, United Kingdom

  • Investigational Site Number : 826001

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.